Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 190-198

  Gardner, Ginger J ^a   Reidy Lagunes, Diane ^a   Gehrig, Paola A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Carcinoid tumors; Neuroendocrine tumors; Small cell carcinoma

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE; PLATINUM; VINCRISTINE;

ADVANCED CANCER; ALGORITHM; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOID; DRUG MECHANISM; FATIGUE; FEMALE GENITAL TRACT TUMOR; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; HUMAN; INSULAR CARCINOID; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; MUCINOUS CARCINOID; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEUROENDOCRINE TUMOR; OVARY CARCINOID; OVARY NEUROENDOCRINE TUMOR; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SMALL CELL CARCINOMA; TRABECULAR CARCINOID; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX NEUROENDOCRINE TUMOR; UTERUS SMALL CELL CARCINOMA; VAGINA SMALL CELL CARCINOMA; VULVA SMALL CELL CARCINOMA; WEIGHT REDUCTION;

COMBINED MODALITY THERAPY; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEUROENDOCRINE TUMORS;

EID: 79957716401     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.011     Document Type: Review

References (121)

1. Moertel C, Kvols L, O'Connell M, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence ofmajor therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
3. Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 1997;121:34-9.
4. Ambros RA, Park JS, Shah KV, Kurman RJ. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol 1991;4:586-93.
5. Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991;15:28-32.
6. Walker AN, Mills SE, Taylor PT. Cervical neuroendocrine carcinoma: a clinical and light microscopic study of 14 cases. Int J Gynecol Pathol 1988;7:64-74. (Pubitemid 18070449)
7. Gersell DJ, Mazoujian G, Mutch DG, Rudloff MA. Small-cell undifferentiated carcinoma of the cervix. A clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol 1988;12:684-98.
8. Lee SW, Nam JH, Kim DY, Kim JH, Kim KR, Kim YM, et al. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case - control study. Int J Gynecol Cancer 2010;20:411-6.
9. Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol 1997;21:905-14. (Pubitemid 27402809)
10. McCusker ME, Cote TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 2003;88:333-9. (Pubitemid 36331986)
11. Scully RE, Aguirre P, DeLellis RA. Argyrophilia, serotonin, and peptide hormones in the female genital tract and its tumors. Int J Gynecol Pathol 1984;3:51-70. (Pubitemid 14123650)
12. Miller B, Dockter M, el Torky M, Photopulos G. Small cell carcinoma of the cervix: a clinical and flow-cytometric study. Gynecol Oncol 1991;42:27-33.
13. Van Nagell Jr JR, Donaldson ES, Wood EG, Maruyama Y, Utley J. Small cell cancer of the uterine cervix. Cancer 1977;40:2243-9. (Pubitemid 8239713)
14. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer 2003;97:568-74. (Pubitemid 36125833)
15. Hirahatake K, Hareyama H, Kure R, Kawaguchi I, Yamaguchi J, Sakuragi N, et al. Cytologic and hormonal findings in a carcinoid tumor of the uterine cervix. Acta Cytol 1990;34:119-24. (Pubitemid 20126105)
16. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107-8.
17. Wentz WB, Reagan JW. Survival in cervical cancer with respect to cell type. Cancer 1959;12:384-8.
18. van Nagell Jr JR, Powell DE, Gallion HH, Elliott DG, Donaldson ES, Carpenter AE, et al. Small cell carcinoma of the uterine cervix. Cancer 1988;62:1586-93.
19. Baum RP, Swietaszczyk C, Prasad V. FDG-PET/CT in lung cancer: an update. Front Radiat Ther Oncol 2010;42:15-45.
20. Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009;15:2426-32.
21. Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C,Wong F, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 2003;21:3495-501. (Pubitemid 46594083)
22. Embry JR, Kelly MG, Post MD, Spillman MA. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantagewith platinumchemotherapy. Gynecol Oncol 2011;120:444-8.
23. Dowell JE. Small cell lung cancer: are we making progress? Am J Med Sci 2010;339:68-76.
24. Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come. J Thorac Cardiovasc Surg 2005;129:64-72. (Pubitemid 40038097)
25. Bischof M, Debus J, Herfarth K, Muley T, Kappes J, Storz K, et al. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlenther Onkol 2007;183:679-84. (Pubitemid 350175411)
26. Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987;71:941-4. (Pubitemid 17151371)
27. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7. (Pubitemid 46623178)
28. Boruta II DM, Schorge JO, Duska LA, Crum CP, Castrillon DH, Sheets EE. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol 2001;81:82-7. (Pubitemid 32368083)
29. Sheets EE, Berman ML, Hrountas CK, Liao SY, DiSaia PJ. Surgically treated, earlystage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol 1988;71:10-4. (Pubitemid 18025069)
30. Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004;93:27-33. (Pubitemid 38429545)
31. Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 1998;83:712-8. (Pubitemid 28387694)
32. Sevin BU, Method MW, Nadji M, Lu Y, Averette HA. Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer 1996;77:1489-93. (Pubitemid 26105384)
33. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-9. (Pubitemid 46594108)
34. Novak J, Escobedo-Morse A, Kelley K, Boose D, Kautzman-Eades D, Meyer M, et al. Nicotine effects on proliferation and the bombesin-like peptide autocrine system in human small cell lung carcinoma SHP77 cells in culture. Lung Cancer 2000;29:1-10. (Pubitemid 30398554)
35. Zivanovic O, Leitao Jr MM, Park KJ, Zhao H, Diaz JP, Konner J, et al. Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol 2009;112:590-3.
36. Trinh XB, Bogers JJ, Van Marck EA, Tjalma WA. Treatment policy of neuroendocrine small cell cancer of the cervix. Eur J Gynaecol Oncol 2004;25:40-4. (Pubitemid 38165918)
37. Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, et al. Prognostic factors in FIGOstage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol 2008;19:321-6.
38. O'Hanlan KA, Goldberg GL, Jones JG, Runowicz CD, Ehrlich L, Rodriguez-Rodriguez L. Adjuvant therapy for neuroendocrine small cell carcinoma of the cervix: review of the literature. Gynecol Oncol 1991;43:167-72.
39. Lewandowski GS, Copeland LJ. A potential role for intensive chemotherapy in the treatment of small cell neuroendocrine tumors of the cervix. Gynecol Oncol 1993;48:127-31. (Pubitemid 23056198)
40. Collinet P, Lanvin D, Declerck D, Chevalier-Place A, Leblanc E, Querleu D. Neuroendocrine tumors of the uterine cervix. Clinicopathologic study of five patients. Eur J Obstet Gynecol Reprod Biol 2000;91:51-7. (Pubitemid 30246019)
41. Abulafia O, Sherer DM. Adjuvant chemotherapy in stage IB neuroendocrine small cell carcinoma of the cervix. Acta Obstet Gynecol Scand 1995;74:740-4.
42. Morris M, Gershenson DM, Eifel P, Silva EG, Mitchell MF, Burke TW, et al. Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecol Oncol 1992;47:62-5.
43. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-61.
44. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91.
45. Chang TC, Hsueh S, Lai CH, Tseng CJ, Lee KF, Huang KG, et al. Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer. Anticancer Drugs 1999;10:641-6. (Pubitemid 29450205)
46. Bermudez A, Vighi S, Garcia A, Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol Oncol 2001;82:32-9. (Pubitemid 32634951)
47. Weed Jr JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg 2003;197:44-51. (Pubitemid 36759178)
48. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91. (Pubitemid 46849574)
49. Young RH, Goodman A, Penson RT, Russell AH, Uppot RN, Tambouret RH. Case records of the Massachusetts General Hospital. Case 8-2010. a 22-year-old woman with hypercalcemia and a pelvic mass. N Engl J Med 2010;362:1031-40.
50. van Hoeven KH, Hudock JA, Woodruff JM, Suhrland MJ. Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol 1995;14:21-9.
51. Crowder S, Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol 2007;34:57-63. (Pubitemid 46161760)
52. Katahira A, Akahira J, Niikura H, Ito K, Moriya T, Matsuzawa S, et al. Small cell carcinoma of the endometrium: report of three cases and literature review. Int J Gynecol Cancer 2004;14:1018-23. (Pubitemid 39238193)
53. Huntsman DG, Clement PB, Gilks CB, Scully RE. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol 1994;18:364-75. (Pubitemid 24093601)
54. Manivel C, Wick MR, Sibley RK. Neuroendocrine differentiation in mullerian neoplasms. An immunohistochemical study of a "pure" endometrial small-cell carcinoma and a mixed mullerian tumor containing small-cell carcinoma. Am J Clin Pathol 1986;86:438-43.
55. Olson N, Twiggs L, Sibley R. Small-cell carcinoma of the endometrium: light microscopic and ultrastructural study of a case. Cancer 1982;50:760-5. (Pubitemid 12052727)
56. Kaminski JM, Anderson PR, Han AC, Mitra RK, Rosenblum NG, Edelson MI. Primary small cell carcinoma of the vagina. Gynecol Oncol 2003;88:451-5. (Pubitemid 36332006)
57. Elsaleh H, Bydder S, Cassidy B, Thompson J. Small cell carcinoma of the vagina. Australas Radiol 2000;44:336-7. (Pubitemid 30658629)
58. Cliby W, Soisson AP, Berchuck A, Clarke-Pearson DL. Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy. Cancer 1991;67:2415-7.
59. Finan MA, Barre G. Bartholin's gland carcinoma, malignant melanoma and other rare tumours of the vulva. Best Pract Res Clin Obstet Gynaecol 2003;17:609-33. (Pubitemid 37168283)
60. Albores-Saavedra J, Larraza O, Poucell S, Rodriguez Martinez HA. Carcinoid of the uterine cervix: additional observations on a new tumor entity. Cancer 1976;38:2328-42. (Pubitemid 8015868)
61. Albores-Saavedra J, Rodriguez-Martinez HA, Larraza-Hernandez O. Carcinoid tumors of the cervix. Pathol Annu 1979;14(Pt 1):273-91.
62. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009;40:1262-8.
63. Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol 2009;6:143-52.
64. Asnacios A, Courbon F, Rochaix P, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26:963-70. (Pubitemid 351398091)
65. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
66. Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986;81:41-8.
67. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-49. (Pubitemid 36337325)
68. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007;25:1967-73.
69. Jacobsen MB, Nitter-Hauge S, Bryde PE, Hanssen LE. Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J 1995;16:263-8.
70. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J 1997;134:693-702. (Pubitemid 27465065)
71. Chaowalit N, Connolly HM, Schaff HV, Webb MJ, Pellikka PA. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol 2004;93:1314-5. (Pubitemid 38595695)
72. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-68. (Pubitemid 29142631)
73. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59. (Pubitemid 36173145)
74. Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol 1996;61:259-65. (Pubitemid 26145734)
75. Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer 1975;36:404-18.
76. Motoyama T, Katayama Y, Watanabe H, Okazaki E, Shibuya H. Functioning ovarian carcinoids induce severe constipation. Cancer 1992;70:513-8.
77. Matsuda K, Maehama T, Kanazawa K. Strumal carcinoid tumor of the ovary: a case exhibiting severe constipation associated with PYY. Gynecol Oncol 2002;87:143-5. (Pubitemid 36027115)
78. Vergani D, Massironi L, Lombardi F, Fiorentini C. Carcinoid heart disease from ovarian primary presenting with acute pericarditis and biventricular failure. Heart 1998;80:623-6. (Pubitemid 28561701)
79. Soga J, Osaka M, Yakuwa Y. Carcinoids of the ovary: an analysis of 329 reported cases. J Exp Clin Cancer Res 2000;19:271-80.
80. Robboy SJ. Insular carcinoid of ovary associated with malignant mucinous tumors. Cancer 1984;54:2273-6. (Pubitemid 15210819)
81. Robboy SJ, Scully RE, Norris HJ. Carcinoid metastatic to the ovary. A clinocopathologic analysis of 35 cases. Cancer 1974;33:798-811.
82. Talerman A, Evans MI. Primary trabecular carcinoid tumor of the ovary. Cancer 1982;50:1403-7. (Pubitemid 12031965)
83. Robboy SJ, Scully RE, Norris HJ. Primary trabecular carcinoid of the ovary. Obstet Gynecol 1977;49:202-7. (Pubitemid 8041220)
84. Yaegashi N, Tsuiki A, Shimizu T, Kobayashi N, Sato S, Namiki T, et al. Ovarian carcinoid with severe constipation due to peptide YY production. Gynecol Oncol 1995;56:302-6.
85. Kawano K, Ushijima K, Fujimoto T, Komai K, Kamura T. Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. J Obstet Gynaecol Res 2007;33:392-6. (Pubitemid 46934566)
86. Alenghat E, Okagaki T, Talerman A. Primary mucinous carcinoid tumor of the ovary. Cancer 1986;58:777-83. (Pubitemid 16072084)
87. Baker PM, Oliva E, Young RH, Talerman A, Scully RE. Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases. Am J Surg Pathol 2001;25:557-68.
88. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-73. (Pubitemid 39004355)
89. Harrison ML, Hoskins P, du Bois A, Quinn M, Rustin GJ, Ledermann JA, et al. Small cell of the ovary, hypercalcemic type - analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol 2006;100:233-8.
90. Pruett KM, Gordon AN, Estrada R, Lynch GR. Small-cell carcinoma of the ovary: an aggressive epithelial cancer occurring in young patients. Gynecol Oncol 1988;29:365-9. (Pubitemid 18079534)
91. Wynn D, Everett GD, Boothby RA. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol Oncol 2004;95:716-8. (Pubitemid 39592543)
92. Dykgraaf RH, de Jong D, van Veen M, Ewing-Graham PC, Helmerhorst TJ, van der Burg ME. Clinical management of ovarian small-cell carcinoma of the hypercalcemic type: a proposal for conservative surgery in an advanced stage of disease. Int J Gynecol Cancer 2009;19:348-53.
93. Patsner B, Piver MS, Lele SB, Tsukada Y, Bielat K, Castillo NB. Small cell carcinoma of the ovary: a rapidly lethal tumor occurring in the young. Gynecol Oncol 1985;22:233-9. (Pubitemid 16215242)
94. Powell JL, McAfee RD, McCoy RC, Shiro BS. Uterine and ovarian conservation in advanced small cell carcinoma of the ovary. Obstet Gynecol 1998;91:846-8. (Pubitemid 28186101)
95. Liu DM, Kennedy A, Turner D, Rose SC, Kee ST, Whiting S, et al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol 2009;32:200-15.
96. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997;122:1147-54 discussion 1154-5.
97. Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999;19:399-414.
98. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31:271-9.
99. Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247:1029-35. (Pubitemid 351770424)
100. Faiss S, Rath U, Mansmann Uea. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 1996;142:193-207.
101. Weslin S, Janson E, Sundin A. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumors. Eur J Endocrinol 2004;151:107-12. (Pubitemid 39117371)
102. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
103. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111.
104. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-6. (Pubitemid 16055931)
105. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9.
106. Schnirer II, Yao JC, Ajani JA. Carcinoid-a comprehensive review. Acta Oncol 2003;42:672-92.
107. Fazio N, de Braud F, Delle Fave G, Oberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 2007;18:13-9.
108. Fjallskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35-42. (Pubitemid 34587755)
109. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23.
110. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park) 2008;22:1617-23 discussion 1623-4, 1629.
111. Cheng P, Saltz L. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-8. (Pubitemid 29439847)
112. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):S111-4.
113. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-904. (Pubitemid 46223995)
114. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548-54. (Pubitemid 46630525)
115. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10.
116. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54. (Pubitemid 44660065)
117. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
118. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
119. Hobday T, Rubin J, Holen K, Picus J, Donehower R, Marschke R, et al. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): a Phase II consortium (P2C) study. J Clin Oncol. In: Oncol JC, editor. American Society of Clinical Oncology, vol. 25. J Clinical Oncology; 2007. Orlando, Florida. abstract 4504.
120. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-8.
121. Yao J, Hainsworth E, Baudin M, et al. Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). American Society of Clinical Oncology Gastrointestinal Symposium. San Francisco, CA, 29; 2011. (Suppl. 4; abstr 159).